BioArctic AB Class B BIOA B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 293.00
- Day Range
- SEK 287.20–293.80
- 52-Week Range
- SEK 257.00–364.40
- Bid/Ask
- SEK 287.20 / SEK 287.60
- Shares Outstanding
- 88.74M
- Market Cap
- SEK 25.51B
- Volume/Avg
- 82,950 / 134,886
Key Statistics
- Price/Earnings (Normalized)
- 243.73
- Price/Sales
- 25.51
- Dividend Yield (Trailing)
- 0.70%
- Dividend Yield (Forward)
- 0.70%
- Dividend Payment Schedule
- Jun
- Total Yield
- 0.70%
Company Profile
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 150
- Website
- https://www.bioarctic.se
Valuation
|
Metric
|
BIOA B
|
|---|---|
Price/Earnings (Normalized) | 243.73 |
Price/Book Value | 12.66 |
Price/Sales | 25.51 |
Price/Cash Flow | 85.20 |
Price/Earnings
BIOA B
Financial Strength
|
Metric
|
BIOA B
|
|---|---|
Quick Ratio | 2.97 |
Current Ratio | 3.99 |
Interest Coverage | 22.93 |
Quick Ratio
BIOA B
Profitability
|
Metric
|
BIOA B
|
|---|---|
Return on Assets (Normalized) | 4.06% |
Return on Equity (Normalized) | 5.18% |
Return on Invested Capital (Normalized) | 3.53% |
Return on Assets
BIOA B
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|w&J>b>Z | LOCK|y$x% | $127B | |||
| Moderna Inc
MRNA
| LOCK|KKj<br | LOCK|ml^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V>^CJT | LOCK|#&bdY | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>fg^QG | LOCK|mY | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hff@RFM | LOCK|&% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|k#XLnn | LOCK|>dFF% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^P%<YT> | LOCK|#Hv>> | $27B | |||
| Incyte Corp
INCY
| LOCK|!k&DPS | LOCK|Hz | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!<@><@> | LOCK|MdY | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|V#bs!!@ | LOCK|Ty? | $14B |
United States